Brief: Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer’S Disease
26/03/2025 12:07
March 26 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O: ACUMEN PHARMACEUTICALS COMPLETES ENROLLMENT OF ALTITUDE-AD, A PHASE 2 CLINICAL TRIAL OF SABIRNETUG (ACU193) IN EARLY ALZHEIMER’S DISEASE ACUMEN PHARMACEUTICALS INC - TOPLINE RESULTS EXPECTED IN LATE 2026 Source text: ID:nGNX3Vt03J Further company coverage: ABOS.O ((Reuters.Briefs@thomsonreuters.com;))